Excellent safety, tolerability and pharmacokinetic profile Robust dose-dependent target engagement as measured by ex vivo IL-1β release assay Phase 2…
Leading radiologists to highlight clinical examples demonstrating power of iCAD’s complete suite of ProFound AI Breast Health SolutionsNASHUA, N.H., June…
Board is Committed to Maximizing the Amount of Cash the Company Distributes to Stockholders Decision Follows Recent Sale of Certain…
Phase 2 portion designed to identify the optimal dose for the pivotal Phase 3 portion of the trialSOUTH SAN FRANCISCO,…
Industry veteran brings over two decades of global experience in pharmaceutical, medical devices and biotech industriesLYON, France and CAMBRIDGE, Mass.,…
-- HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of…
Evaluation completed of first dose level in investigator-sponsored study in biochemically recurrent prostate cancer Enrollment initiated for second dose level…
exoASO-STAT6 is the third engineered exosome candidate generated from Codiak’s engEx® Platform to enter clinical development CAMBRIDGE, Mass., June 29,…
Effectively Immediately, Vivos to be Exclusive Distributor for Novel Diagnostic Equipment to Evaluate Nasal Breathing and Function in Dental Patients…
SEATTLE and VANCOUVER, British Columbia, June 29, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical…